Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Fault Detection, Zone MPC and DiAs System in T1D (ZoneMPC)

13 maggio 2016 aggiornato da: B. Wayne Bequette, Rensselaer Polytechnic Institute

A Randomized Crossover Study to Evaluate the Efficacy of Fault Detection Algorithms Using the ZoneMPC Algorithm and DiAs System in Adult Subjects With Type 1 Diabetes in the Outpatient Setting

This is a randomized crossover study testing the efficacy of the Fault Detection algorithms using the Zone MPC algorithm and DiAs artificial pancreas platform in adult patients with type 1 diabetes. The trial will last for 6 weeks for each individual subject, with three weeks using the AP algorithm and three weeks using sensor augmented pump in a randomized order

Panoramica dello studio

Descrizione dettagliata

Investigational Device:

Artificial Pancreas System with Fault Detection Algorithms: Roche Accu-Check Spirit Combo Insulin Pump, Dexcom G4P System with Share, Diabetes Assistant (DiAs) on Android phone, DiAs Web Monitoring (DWM)

- referred to as Remote Monitoring Server, MPC control algorithm, Health Monitoring System (HMS) algorithm. Sensor and infusion set fault detection algorithms will be applied offline with data obtained from server and notifications will be sent to the clinician.

Control Arm:

Sensor-augmented insulin pump therapy: Subject will use their personal insulin pump and Dexcom G4P System with Share.

Primary Objective:

To determine the efficacy of the fault detection algorithm. The primary outcome is based on the amount of time the sensor glucose is >250 mg/dL in the 4 hours preceding detection of the infusion set failure during sensor augmented pump therapy vs. closed-loop control with fault detection alerts.

Secondary Objectives:

To determine the effectiveness of the sensor fault detection algorithm. To determine the efficacy of the Zone MPC controller by evaluating glycemic outcomes

Number of Subjects:

There will be 20 subjects recruited: 10 at Stanford and 10 at Denver (up to 36 subjects will be enrolled to reach 20 subjects completing the study)

Diagnosis and Main Inclusion Criteria:

Adult subjects between 18 and 55 years of age inclusive, diagnosed with type 1 diabetes.

Trial Design:

This outpatient study will be conducted over 6 weeks as shown in the figure below. The 6-week period will consist of two 2-week blocks of prolonged infusion set wear with a 1-week sensor run-in period preceding each block. In each block, subjects will wear an infusion set for up to 7 days. A new infusion set will be inserted at the start of each week in the block. Following enrollment procedures, subjects will be randomized at a ratio of 1:1 to either use the AP system with fault detection algorithms (intervention) or sensor-augmented pump therapy (control) in the first block.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

20

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 55 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Clinical diagnosis of type 1 diabetes for at least 12 months
  2. Daily insulin therapy for at least 12 months
  3. Age between 18.0 to 55.0 years of age
  4. Use of an insulin pump for at least 3 months
  5. Subject comprehends English
  6. Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test
  7. Total daily insulin requirement ≥ 0.3 units/kg/day
  8. Subject has an adult companion, age > 18 years, who lives with the subject, has access to where they sleep, is willing to be in the house when the subject is sleeping and willing to attend to the subject if there are safety concerns -

Exclusion Criteria:

  1. Diabetic ketoacidosis in the past 6 months
  2. Hypoglycemic seizure or loss of consciousness in the past 6 months
  3. Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
  4. Subjects using other anti-diabetic medications other than insulin (oral or injectable) at the time of enrollment. Any prior use of other anti-diabetic medications must be washed out for at least 8 weeks prior to enrollment.
  5. Current use of other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  6. Subject has a medical disorder that in the judgment of the investigator will affect completion of any aspect of the protocol
  7. Subject is currently participating in another investigational device or drug study within 30 days or 5-half-lives of the drug.
  8. Subject has a history of any cardiac or vascular disorder including, but not limited to, myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
  9. Subject has a history of hepatic disease
  10. Subject has renal failure on dialysis
  11. Systolic blood pressure > 160 mmHg on screening visit
  12. Diastolic blood pressure > 90 mmHg on screening visit
  13. Subjects with inadequately treated thyroid disease or celiac disease
  14. Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
  15. Subject has received inpatient psychiatric treatment in the past 6 months
  16. Subject consumes more than an average of 4 standard alcoholic drinks/day in the last 30 days
  17. Subject has an active skin condition that would affect sensor placement
  18. Subject is unable to avoid acetaminophen for the duration of the study
  19. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  20. Subject is currently on beta blocker medication -

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Sensor Augmented Pump (control)
Use sensor augmented pump (SAP) for 3 weeks.
Sperimentale: Artificial Pancreas (intervention)
Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Amount of time sensor glucose levels are >250 mg/dl
Lasso di tempo: 4 hours after insulin infusion set failure
Amount of time sensor glucose levels are >250 mg/dl in the control arm versus the experimental arm
4 hours after insulin infusion set failure

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Effectiveness of sensor fault detection algorithm as defined by % of sensor failures caught by the system
Lasso di tempo: During 2 week intervention period
Effectiveness of sensor fault detection algorithm as defined by % of sensor failures caught by the system
During 2 week intervention period
Mean sensor glucose values
Lasso di tempo: 2 week intervention period versus 2 week control period
mean sensor glucose values
2 week intervention period versus 2 week control period
Percent of time in range between 70-180 mg/dl
Lasso di tempo: 2 week intervention period versus 2 week control period
Percent of time in range between 70-180 mg/dl
2 week intervention period versus 2 week control period

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 maggio 2016

Completamento primario (Anticipato)

1 novembre 2016

Completamento dello studio (Anticipato)

1 dicembre 2016

Date di iscrizione allo studio

Primo inviato

11 maggio 2016

Primo inviato che soddisfa i criteri di controllo qualità

13 maggio 2016

Primo Inserito (Stima)

16 maggio 2016

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

16 maggio 2016

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 maggio 2016

Ultimo verificato

1 maggio 2016

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Diabete di tipo 1

Prove cliniche su Artificial pancreas system (Algorithm + CGM + pump)

3
Sottoscrivi